First Approval of Diagnostic NGS Platforms in Russia
Illumina’s NextSeq 550Dx platform and associated reagent kits received medical device registration in Russia, as have reagents for the MiSeqDx.
Read MorePosted by Melanie Hamilton-Basich | Mar 11, 2021 | Sequencing Systems |
Illumina’s NextSeq 550Dx platform and associated reagent kits received medical device registration in Russia, as have reagents for the MiSeqDx.
Read MorePosted by Laurie Bonner | Mar 9, 2021 | Cancer, Company News, Molecular Diagnostics |
Strategic collaboration combines germline genetic testing, next-generation tumor sequencing, and testing capabilities to elevate precision oncology care.
Read MorePosted by Laurie Bonner | Mar 5, 2021 | Covid 19, POC Reagents & Test Kits |
The product is a molecular nucleic acid amplification test that is intended to detect genetic material from SARS-CoV-2 virus present in the nostrils.
Read MorePosted by Melanie Hamilton-Basich | Mar 3, 2021 | Breast |
The lead researcher says the results will have a positive effect on patient care because patients will know whether breast cancer VUS are benign or pathogenic.
Read MorePosted by Laurie Bonner | Mar 3, 2021 | Covid 19, Molecular Diagnostics |
Reagent shortages during the covid-19 pandemic draw attention to a different method.
Read More